Cardiovascular Diseases Research in New York
Cardiovascular Diseases Research (93.837) awarded $1.4 billion to recipients in New York in 895 grants from fiscal 2021 to 2025, 9.3% of the program's national total. The Trustees of Columbia University in the City of New York received the most, $335 million.
- Awarded in New York$1.4 billion
- Awards895
- Share of the program9.3%
- Rank among states3rd of 51
- National total$15 billion
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 439 | $245 million |
| FY 2022 | 458 | $265 million |
| FY 2023 | 478 | $289 million |
| FY 2024 | 470 | $280 million |
| FY 2025 | 473 | $282 million |
Recipients in New York
| Recipient | Type | Awards | Amount |
|---|---|---|---|
| The Trustees of Columbia University in the City of New York | Colleges and universities | 207 | $335 million |
| New York University | Colleges and universities | 104 | $202 million |
| Icahn School of Medicine at Mount Sinai | Colleges and universities | 129 | $196 million |
| Weill Medical College of Cornell University | Colleges and universities | 106 | $168 million |
| Albert Einstein College of Medicine, Inc. | Colleges and universities | 71 | $98.5 million |
| University of Rochester | Colleges and universities | 73 | $93.4 million |
| New York Blood Center, Inc | Nonprofits | 10 | $28.5 million |
| The Research Foundation for the State University of New York | Other | 22 | $21.7 million |
| The Feinstein Institutes for Medical Research | Nonprofits | 12 | $19.7 million |
| The Trustees of Columbia University in the City of New York | Colleges and universities | 10 | $16.4 million |
Open opportunities under this program
- Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)
- Emerging Global Leader Award (K43 Independent Clinical Trial Required)
- NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed)
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)
- Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)
- NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
- NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
- Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed)
- NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
See all 81 on the program page
Questions people ask
How much Cardiovascular Diseases Research money goes to New York?
$1.4 billion from fiscal 2021 to 2025, across 895 awards. New York ranks 3rd of 51 states and territories for this program.
Who receives Cardiovascular Diseases Research money in New York?
The largest recipient is The Trustees of Columbia University in the City of New York, with $335 million in 207 awards. Next are New York University and Icahn School of Medicine at Mount Sinai.
Can organizations in New York apply now?
Yes, 81 opportunities under this program are open or forecast on Grants.gov. Federal grants are national, so eligibility depends on the notice, not the state.
Cardiovascular Diseases Research in other states
Other large programs in New York
- Grants to States for Medicaid
- 1332 State Innovation Waivers
- Federal Transit Formula Grants
- Education Stabilization Fund
- Disaster Grants - Public Assistance (Presidentially Declared Disasters)
- Temporary Assistance for Needy Families
- Highway Planning and Construction
- National School Lunch Program
- Children's Health Insurance Program
- Public Housing Operating Fund